Noon notice 丨 West pump shares of the real holders of holdings of light rhyme reorganization of the application was accepted

　　The company plans to carry out this non-public offering of shares of the inquiry work, the company's stock since October 21 opened from the suspension, is expected to suspension time of not more than 5 trading days, the subscription object will be the day after the end of the day Resume trading.

　　West pump shares: the controlling shareholder and the actual controller to increase holdings of shares of the company

　　West Pumps (002536) Controlling shareholder Wanxi Holding Plan Within six months from 21 October 2016, the controlling shareholder of the Shenzhen Stock Exchange (including but not limited to centralized and bulk transactions) (Including but not limited to centralized auctions and bulk deals) within six months from 21 October 2016. The actual controller, Sun Yaozhong, plans to increase its holdings through the Shenzhen Stock Exchange trading system (including but not limited to centralized and bulk transactions) The company's total share capital of 0.05% -0.2% of the shares.

　　Tonghua Jinma (15.050, -0.15, -0.99%): Alzheimer's medicine to enter the phase III clinical trials

　　Tonghua Jinma (000766) subsidiary Changchun Huayang Hi-Tech Co., Ltd., Jiangsu Shen Er Yang high-tech Co., Ltd. jointly developed the treatment of senile dementia 1.1 class of new drug amber octahydro-ammonia acridine tablets, in August 2015 Access to the State Food and Drug Administration issued by the Phase III drug clinical trial approval. At present, Huayang and Shen'er Yang have signed a "clinical trial (commissioned) contract with Phase III clinical trial for the Phase III clinical trial of amber octahydrocyclidine with Beijing Bonauxia Pharmaceutical Technology Co., Ltd. to complete the trial The production of goods and reference products, access to the ethics committee issued by the ethical approval. According to the relevant regulations, amber octahydroamide acridine tablets can be formally entered the phase III clinical trials. Amber octahydroaminasaline tablets Phase III clinical trials are successful, whether the future access to the State Food and Drug Administration listed on the approval, with a certain degree of uncertainty.

　　Light rhyme: reorganization of the application by the SFC accepted

　　Guangyun (300227) on October 21, 2016 received the China Securities Regulatory Commission, "China Securities Regulatory Commission to accept the application for administrative license notice," the company submitted to accept the material. The Company's issuance of shares and the payment of cash to purchase assets and to raise matching funds are subject to the approval of the CSRC.

　　(27.150, -0.49, -1.77%) correction 2016 annual net profit fluctuation range expected

　　The Company announces that the net profit attributable to shareholders of the Company in 2016 will be revised from 120.00% to 170.00% to 20.00% to 70.00%.